Compare Inovio Pharmaceuticals Inc (INO) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Phillips 66 — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Phillips 66 trades at $278.8 (market cap $112.36B). The key difference: Phillips 66 is far larger — about 1001.5× Inovio Pharmaceuticals Inc's market cap, and Phillips 66 pays a 1.8% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Phillips 66 for 62 Days on average.
| INO | PSX | |
|---|---|---|
Market Cap | $112.19M | $112.36B |
Volume | 3,201,278 | 2,374,751 |
Sector | Health | Energy |
52-Week High | $2.65 | $281.60 |
52-Week Low | $0.66 | $126.76 |
Typical Hold Time | 43 Days | 62 Days |
Enterprise Value | $83.51M | $128.83B |
Dividend Yield | — | 1.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
Phillips 66 (PSX) trades at $283.31, up 4.3% with strong technical momentum and bullish moving average signals. The stock shows solid fundamentals with a P/E of 16.07, ROE of 24.02%, and consistent earnings beats in recent quarters. Recent news highlights structural refining advantages and AI implementation for operational efficiency, while analyst consensus remains positive with 54% buy ratings.
PSX presents a compelling investment case with strong profitability metrics and positive earnings momentum, though investors face risks from volatile energy markets and potential policy changes affecting diesel exports. The current price sits near consensus targets, suggesting balanced near-term upside potential with structural refining strengths supporting long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
